Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant.
Autorzy:
Ryan KA; UK Health Security Agency, Salisbury, United Kingdom. Bewley KR; UK Health Security Agency, Salisbury, United Kingdom. Watson RJ; UK Health Security Agency, Salisbury, United Kingdom. Burton C; UK Health Security Agency, Salisbury, United Kingdom. Carnell O; UK Health Security Agency, Salisbury, United Kingdom. Cavell BE; UK Health Security Agency, Salisbury, United Kingdom. Challis A; UK Health Security Agency, Salisbury, United Kingdom. Coombes NS; UK Health Security Agency, Salisbury, United Kingdom. Davies ER; UK Health Security Agency, Salisbury, United Kingdom. Edun-Huges J; UK Health Security Agency, Salisbury, United Kingdom. Emery K; UK Health Security Agency, Salisbury, United Kingdom. Fell R; UK Health Security Agency, Salisbury, United Kingdom. Fotheringham SA; UK Health Security Agency, Salisbury, United Kingdom. GoochKE; UK Health Security Agency, Salisbury, United Kingdom. Gowan K; UK Health Security Agency, Salisbury, United Kingdom. Handley A; UK Health Security Agency, Salisbury, United Kingdom. Harris DJ; UK Health Security Agency, Salisbury, United Kingdom. Hesp R; UK Health Security Agency, Salisbury, United Kingdom. Hunter L; UK Health Security Agency, Salisbury, United Kingdom. Humphreys R; UK Health Security Agency, Salisbury, United Kingdom. Johnson R; UK Health Security Agency, Salisbury, United Kingdom. Kennard C; UK Health Security Agency, Salisbury, United Kingdom. Knott D; UK Health Security Agency, Salisbury, United Kingdom. Lister S; UK Health Security Agency, Salisbury, United Kingdom. Morley D; UK Health Security Agency, Salisbury, United Kingdom. Ngabo D; UK Health Security Agency, Salisbury, United Kingdom. Osman KL; UK Health Security Agency, Salisbury, United Kingdom. Paterson J; UK Health Security Agency, Salisbury, United Kingdom. Penn EJ; UK Health Security Agency, Salisbury, United Kingdom. Pullan ST; UK Health Security Agency, Salisbury, United Kingdom. Richards KS; UK Health Security Agency, Salisbury, United Kingdom. Summers S; UK Health Security Agency, Salisbury, United Kingdom. Thomas SR; UK Health Security Agency, Salisbury, United Kingdom. Weldon T; UK Health Security Agency, Salisbury, United Kingdom. Wiblin NR; UK Health Security Agency, Salisbury, United Kingdom. Rayner EL; UK Health Security Agency, Salisbury, United Kingdom. Vipond RT; UK Health Security Agency, Salisbury, United Kingdom. Hallis B; UK Health Security Agency, Salisbury, United Kingdom. Salguero FJ; UK Health Security Agency, Salisbury, United Kingdom. Funnell SGP; UK Health Security Agency, Salisbury, United Kingdom. Hall Y; UK Health Security Agency, Salisbury, United Kingdom.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2023 Apr 04; Vol. 19 (4), pp. e1011293. Date of Electronic Publication: 2023 Apr 04 (Print Publication: 2023).
SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum.
Autorzy:
Handley A; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Ryan KA; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Davies ER; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Bewley KR; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Carnell OT; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Challis A; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Coombes NS; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Fotheringham SA; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. GoochKE; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Charlton M; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Harris DJ; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Kennard C; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Ngabo D; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Weldon TM; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Salguero FJ; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK. Funnell SGP; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.; Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK.; World Health Organization, Appia 20, 1211 Geneva, Switzerland. Hall Y; UKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Mar 14; Vol. 15 (3). Date of Electronic Publication: 2023 Mar 14.
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.
Autorzy:
Lambe T; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Spencer AJ; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Thomas KM; National Infection Service, Public Health England, Salisbury, UK. GoochKE; National Infection Service, Public Health England, Salisbury, UK. Thomas S; National Infection Service, Public Health England, Salisbury, UK. White AD; National Infection Service, Public Health England, Salisbury, UK. Humphries HE; National Infection Service, Public Health England, Salisbury, UK. Wright D; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Belij-Rammerstorfer S; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Thakur N; The Pirbright Institute, Woking, Surrey, UK. Conceicao C; The Pirbright Institute, Woking, Surrey, UK. Watson R; National Infection Service, Public Health England, Salisbury, UK. Alden L; National Infection Service, Public Health England, Salisbury, UK. Allen L; National Infection Service, Public Health England, Salisbury, UK. Aram M; National Infection Service, Public Health England, Salisbury, UK. Bewley KR; National Infection Service, Public Health England, Salisbury, UK. Brunt E; National Infection Service, Public Health England, Salisbury, UK. Brown P; National Infection Service, Public Health England, Salisbury, UK. Cavell BE; National Infection Service, Public Health England, Salisbury, UK. Cobb R; National Infection Service, Public Health England, Salisbury, UK. Fotheringham SA; National Infection Service, Public Health England, Salisbury, UK. Gilbride C; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Harris DJ; National Infection Service, Public Health England, Salisbury, UK. Ho CMK; National Infection Service, Public Health England, Salisbury, UK. Hunter L; National Infection Service, Public Health England, Salisbury, UK. Kennard CL; National Infection Service, Public Health England, Salisbury, UK. Leung S; National Infection Service, Public Health England, Salisbury, UK. Lucas V; National Infection Service, Public Health England, Salisbury, UK. Ngabo D; National Infection Service, Public Health England, Salisbury, UK. Ryan KA; National Infection Service, Public Health England, Salisbury, UK. Sharpe H; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Sarfas C; National Infection Service, Public Health England, Salisbury, UK. Sibley L; National Infection Service, Public Health England, Salisbury, UK. Slack GS; National Infection Service, Public Health England, Salisbury, UK. Ulaszewska M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Wand N; National Infection Service, Public Health England, Salisbury, UK. Wiblin NR; National Infection Service, Public Health England, Salisbury, UK. Gleeson FV; Department of Oncology, University of Oxford, Oxford, UK. Bailey D; The Pirbright Institute, Woking, Surrey, UK. Sharpe S; National Infection Service, Public Health England, Salisbury, UK. Charlton S; National Infection Service, Public Health England, Salisbury, UK. Salguero FJ; National Infection Service, Public Health England, Salisbury, UK. Carroll MW; National Infection Service, Public Health England, Salisbury, UK.; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Gilbert SC; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2021 Jul 26; Vol. 4 (1), pp. 915. Date of Electronic Publication: 2021 Jul 26.
High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.
Autorzy:
Sibley L; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. . White AD; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. GoochKE; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Stevens LM; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Tanner R; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK. Jacobs A; University of Cape Town, Cape Town, South Africa. Daykin-Pont O; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Gleeson F; Churchill Hospital, Headington, Oxford, UK. McIntyre A; Churchill Hospital, Headington, Oxford, UK. Basaraba R; Colorado State University, Fort Collins, CO, USA. Clark S; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Hall G; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Pearson G; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Rayner E; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. McShane H; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK. Williams A; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Dennis M; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Marsh PD; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. Sharpe S; National Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jun 10; Vol. 11 (1), pp. 12274. Date of Electronic Publication: 2021 Jun 10.
Heterosubtypic cross-protection correlates with cross-reactive interferon-gamma-secreting lymphocytes in the ferret model of influenza.
Autorzy:
GoochKE; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Marriott AC; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. . Ryan KA; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Yeates P; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Slack GS; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Brown PJ; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Fothergill R; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Whittaker CJ; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom. Carroll MW; National Infection Service, Public Health England, Porton Down, SP4 0JG, United Kingdom.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Feb 22; Vol. 9 (1), pp. 2617. Date of Electronic Publication: 2019 Feb 22.
Cellular immune response to human influenza viruses differs between H1N1 and H3N2 subtypes in the ferret lung.
Autorzy:
Ryan KA; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Slack GS; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Marriott AC; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Kane JA; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Whittaker CJ; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Silman NJ; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Carroll MW; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. GoochKE; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Sep 07; Vol. 13 (9), pp. e0202675. Date of Electronic Publication: 2018 Sep 07 (Print Publication: 2018).
Influenza A Virus Challenge Models in Cynomolgus Macaques Using the Authentic Inhaled Aerosol and Intra-Nasal Routes of Infection.
Autorzy:
Marriott AC; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Dennis M; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Kane JA; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. GoochKE; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Hatch G; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Sharpe S; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Prevosto C; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Leeming G; Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Zekeng EG; Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Staples KJ; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. Hall G; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Ryan KA; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Bate S; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Moyo N; Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Whittaker CJ; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Hallis B; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Silman NJ; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom. Lalvani A; Department of Respiratory Infections, National Heart and Lung Institute, Imperial College, London, United Kingdom. Wilkinson TM; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. Hiscox JA; Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Stewart JP; Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Carroll MW; National Infection Service, Public Health England, Porton Down, Wiltshire, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Jun 16; Vol. 11 (6), pp. e0157887. Date of Electronic Publication: 2016 Jun 16 (Print Publication: 2016).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
